ISRCTN16585188 https://doi.org/10.1186/ISRCTN16585188

Phase I Trial: 323476

Submission date 10/09/2024	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 13/09/2024	**Overall study status** Deferred	
Last Edited 28/10/2026	**Condition category** Other	

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Scientific, Principal investigator

Contact name
Prof Amanda Adler

Contact details
University of Oxford, Diabetes Trial Unit
Oxford
United Kingdom
OX3 7LJ
-
enquiries@rdm.ox.ac.uk

Type(s)
Public

Contact name
Dr Information Team

Contact details
117 Charterhouse Street
London
United Kingdom
EC1M 6AA
-
info@sava.health

Additional identifiers

Integrated Research Application System (IRAS)
323476

Central Portfolio Management System (CPMS)
59146

Study information

Scientific Title
The full scientific title will be published within 30 months after the end of the trial

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 22/03/2024, London - Dulwich Research Ethics Committee (2nd Floor, 2 Redman Place, London, E20 1JO, United Kingdom; 0207 104 8290; dulwich.rec@hra.nhs.uk), ref: 24/LO/0134

Primary study design
Interventional

Study design
Multi-site trial with 50 participants

Study type(s)
Other

Health condition(s) or problem(s) studied
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Device

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
07/08/2025

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Other

Healthy volunteers allowed
No

Age group
Not Specified

Sex
All

Total final enrolment
0

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
24/11/2024

Date of final enrolment
28/07/2025

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Addenbrooke's Hospital Laboratory
Addenbrookes Hospital
Hills Road
Cambridge
England
CB2 0QQ

Sponsor information

Organisation
SAVA Technologies Ltd.

Funder(s)

Funder type
Industry

Funder Name
SAVA Technologies Ltd.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available